Paradigm doses first subjects in Phase III knee osteoarthritis trial
The trial will evaluate the change in pain and function following subcutaneous injections of PPS versus placebo.

The trial will evaluate the change in pain and function following subcutaneous injections of PPS versus placebo.
The trial will evaluate the safety, pharmacokinetics and efficacy of SL-1002 in adults with limb spasticity.
The trial will assess the safety, tolerability and pharmacokinetics of TST002 to treat individuals with osteoporosis.
The trial failed to meet the primary endpoint but showed a trend favouring treatment with 400mg ACP-044.
The 6-minute walk test has long been the consensus primary measure for Pompe disease drug studies, but some experts are…
ByThe change in average daily pain scores from baseline to week 12 is the primary endpoint of the trial.
Subject-reported pain at day 14 due to acute back spasm is the primary goal of the trial.
The US FDA's clinical hold on Zolgensma did not just delay Novartis in developing the drug, but allowed its competitors…
By